Puma Biotechnology Inc (NYSE:PBYI): Set To Fly High In 2014 With Neratinib

31-12-2013 iStockAnalyst (press release)Comments (0)

BiotechnologyPuma Biotech

The year 2014 could be a transformative one for Puma Biotechnology Inc (NYSE:PBYI) as neratinib offers potential upside opportunity. Puma's key development compound is an agent for HER2+ disease called neratinib. HER2-positive breast cancer is a ...

Read more on iStockAnalyst (press release)

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top